HK1015261A1 - Stabilizing formulation for ngf - Google Patents

Stabilizing formulation for ngf

Info

Publication number
HK1015261A1
HK1015261A1 HK99100226A HK99100226A HK1015261A1 HK 1015261 A1 HK1015261 A1 HK 1015261A1 HK 99100226 A HK99100226 A HK 99100226A HK 99100226 A HK99100226 A HK 99100226A HK 1015261 A1 HK1015261 A1 HK 1015261A1
Authority
HK
Hong Kong
Prior art keywords
ngf
stabilizing formulation
stabilizing
formulation
maturation
Prior art date
Application number
HK99100226A
Other languages
English (en)
Inventor
Linda R De Young
Xanthe M Lam
Tue Nguyen
Michael F Powell
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24214304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1015261(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1015261A1 publication Critical patent/HK1015261A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
HK99100226A 1995-11-07 1999-01-16 Stabilizing formulation for ngf HK1015261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468595A 1995-11-07 1995-11-07
PCT/US1996/016881 WO1997017087A1 (en) 1995-11-07 1996-10-21 Stabilizing formulation for ngf

Publications (1)

Publication Number Publication Date
HK1015261A1 true HK1015261A1 (en) 1999-10-15

Family

ID=24214304

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99100226A HK1015261A1 (en) 1995-11-07 1999-01-16 Stabilizing formulation for ngf

Country Status (18)

Country Link
EP (1) EP0862452B1 (xx)
JP (1) JP4057058B2 (xx)
KR (1) KR100497087B1 (xx)
CN (1) CN1126567C (xx)
AT (1) ATE255903T1 (xx)
AU (1) AU721112B2 (xx)
BR (1) BR9611571B1 (xx)
CA (1) CA2234231C (xx)
DE (1) DE69631063T2 (xx)
DK (1) DK0862452T3 (xx)
ES (1) ES2211991T3 (xx)
HK (1) HK1015261A1 (xx)
IL (1) IL124004A (xx)
MX (1) MX9803342A (xx)
PT (1) PT862452E (xx)
TR (1) TR199800811T2 (xx)
WO (1) WO1997017087A1 (xx)
ZA (1) ZA969290B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286137A1 (en) * 1997-04-11 1998-10-22 Roche Diagnostics Gmbh Ngf for the prevention of demyelination in the nervous system
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
WO2000004913A1 (en) † 1998-07-23 2000-02-03 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CA2452114C (en) * 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Tgf-.beta. superfamily production/secretion promoter
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
KR101105486B1 (ko) 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
CN108348579B (zh) * 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物及注射粉剂
WO2017117701A1 (zh) * 2016-01-04 2017-07-13 葡萄王生技股份有限公司 预防听力退化的活性物质、含其的组合物、及其制备方法
CN114252519B (zh) * 2020-09-23 2023-11-24 舒泰神（北京）生物制药股份有限公司 一种测定神经生长因子纯度的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor

Also Published As

Publication number Publication date
EP0862452A1 (en) 1998-09-09
KR100497087B1 (ko) 2005-09-09
CN1201394A (zh) 1998-12-09
PT862452E (pt) 2004-04-30
DK0862452T3 (da) 2004-04-05
ATE255903T1 (de) 2003-12-15
JP4057058B2 (ja) 2008-03-05
CA2234231C (en) 2009-04-14
JP2002502358A (ja) 2002-01-22
ES2211991T3 (es) 2004-07-16
BR9611571B1 (pt) 2009-01-13
BR9611571A (pt) 1999-03-30
MX9803342A (es) 1998-09-30
TR199800811T2 (xx) 1998-07-21
AU7518696A (en) 1997-05-29
CN1126567C (zh) 2003-11-05
AU721112B2 (en) 2000-06-22
CA2234231A1 (en) 1997-05-15
IL124004A (en) 2003-10-31
DE69631063D1 (de) 2004-01-22
EP0862452B1 (en) 2003-12-10
DE69631063T2 (de) 2004-09-30
ZA969290B (en) 1998-05-05
WO1997017087A1 (en) 1997-05-15
KR19990067350A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
ZA969290B (en) Stabilizing formulation for NGF.
PL313084A1 (en) Pharmaceutic formulation of nerve growth factor
AU644610B2 (en) Synergistic microbicidal combinations
AU693747B2 (en) Imidazo(4,5-c)pyridin-4-amines
AU4718496A (en) Use of aerogels in agriculture
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
SI0785948T1 (en) Analogs of keratinocyte growth factor
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
PH31320A (en) Fenbendazole formulations.
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
GR3029319T3 (en) Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity
AU4299696A (en) Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells
EP0820507B8 (en) Ndf peptides
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20161020